Teva Pharmaceutical Industries Limited (NYSE:TEVA) Expected to Announce Quarterly Sales of $3.82 Billion

Brokerages expect Teva Pharmaceutical Industries Limited (NYSE:TEVAGet Rating) to post $3.82 billion in sales for the current fiscal quarter, according to Zacks Investment Research. Five analysts have provided estimates for Teva Pharmaceutical Industries’ earnings, with the highest sales estimate coming in at $3.90 billion and the lowest estimate coming in at $3.75 billion. Teva Pharmaceutical Industries posted sales of $3.91 billion during the same quarter last year, which suggests a negative year-over-year growth rate of 2.3%. The company is scheduled to announce its next earnings report on Monday, January 1st.

According to Zacks, analysts expect that Teva Pharmaceutical Industries will report full year sales of $15.71 billion for the current financial year, with estimates ranging from $15.54 billion to $16.00 billion. For the next financial year, analysts expect that the business will report sales of $15.99 billion, with estimates ranging from $15.48 billion to $16.38 billion. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side analysts that follow Teva Pharmaceutical Industries.

Teva Pharmaceutical Industries (NYSE:TEVAGet Rating) last posted its quarterly earnings results on Tuesday, May 3rd. The company reported $0.55 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.55. The firm had revenue of $3.66 billion for the quarter, compared to analysts’ expectations of $3.75 billion. Teva Pharmaceutical Industries had a negative net margin of 3.95% and a positive return on equity of 24.04%. The firm’s quarterly revenue was down 8.1% on a year-over-year basis. During the same period in the prior year, the company posted $0.60 earnings per share.

A number of research analysts have commented on TEVA shares. StockNews.com raised Teva Pharmaceutical Industries from a “hold” rating to a “buy” rating in a report on Thursday, May 12th. Bank of America raised shares of Teva Pharmaceutical Industries from an “underperform” rating to a “neutral” rating and set a $9.00 price objective for the company in a report on Tuesday, May 17th. Argus downgraded shares of Teva Pharmaceutical Industries from a “buy” rating to a “hold” rating in a research report on Thursday, January 27th. Piper Sandler downgraded shares of Teva Pharmaceutical Industries from a “neutral” rating to an “underweight” rating and lowered their price objective for the company from $11.00 to $7.00 in a research report on Wednesday, May 4th. Finally, Barclays raised shares of Teva Pharmaceutical Industries from an “equal weight” rating to an “overweight” rating and raised their target price for the stock from $11.00 to $13.00 in a report on Tuesday, April 5th. One investment analyst has rated the stock with a sell rating, five have given a hold rating and three have given a buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $10.86.

NYSE:TEVA traded up $0.55 during mid-day trading on Wednesday, reaching $9.00. The stock had a trading volume of 11,362,046 shares, compared to its average volume of 8,955,087. The company has a debt-to-equity ratio of 2.03, a current ratio of 1.07 and a quick ratio of 0.73. The company has a market capitalization of $9.93 billion, a price-to-earnings ratio of -16.36, a price-to-earnings-growth ratio of 1.03 and a beta of 1.18. Teva Pharmaceutical Industries has a 1-year low of $7.23 and a 1-year high of $11.55. The stock’s 50 day simple moving average is $8.86 and its two-hundred day simple moving average is $8.58.

In other news, VP David Matthew Stark sold 6,452 shares of the stock in a transaction on Monday, February 28th. The stock was sold at an average price of $8.14, for a total value of $52,519.28. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Eli Shani sold 5,311 shares of Teva Pharmaceutical Industries stock in a transaction dated Monday, February 28th. The shares were sold at an average price of $8.14, for a total transaction of $43,231.54. The disclosure for this sale can be found here. Insiders sold 141,763 shares of company stock worth $1,164,351 in the last 90 days. 0.82% of the stock is owned by company insiders.

Institutional investors have recently bought and sold shares of the company. Weiss Multi Strategy Advisers LLC acquired a new position in shares of Teva Pharmaceutical Industries during the first quarter valued at approximately $393,000. Quantbot Technologies LP bought a new position in Teva Pharmaceutical Industries during the 1st quarter valued at $110,000. Royal Bank of Canada increased its position in shares of Teva Pharmaceutical Industries by 21.6% during the 1st quarter. Royal Bank of Canada now owns 944,421 shares of the company’s stock valued at $8,868,000 after purchasing an additional 167,556 shares during the period. Geneos Wealth Management Inc. raised its stake in shares of Teva Pharmaceutical Industries by 18.1% in the 1st quarter. Geneos Wealth Management Inc. now owns 71,982 shares of the company’s stock worth $675,000 after buying an additional 11,044 shares in the last quarter. Finally, California State Teachers Retirement System lifted its holdings in shares of Teva Pharmaceutical Industries by 1.2% in the first quarter. California State Teachers Retirement System now owns 1,225,575 shares of the company’s stock valued at $11,508,000 after buying an additional 14,277 shares during the period. Institutional investors and hedge funds own 45.79% of the company’s stock.

Teva Pharmaceutical Industries Company Profile (Get Rating)

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams.

Further Reading

Get a free copy of the Zacks research report on Teva Pharmaceutical Industries (TEVA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Teva Pharmaceutical Industries (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.